Micron receives additional funding from the CDC for collaboration on the development of a microneedle patch for IRV-IPV co-administration

ATLANTA, August 27, 2018 – Micron Biomedical, Inc. (Micron) was awarded a new research contract by the Centers for Disease Control and Prevention (CDC) to continue the development of an IRV-IPV microneedle patch and its GMP manufacturing process.  This new research contract comes after Micron successfully completed a Phase 1 SBIR grant and a research contract with the CDC for the development of a microneedle patch for the administration of inactivated rotavirus vaccine (IRV) and co-administration of IRV and inactivated poliovirus vaccine (IPV). The goal of this contract is to continue to advance the preclinical development of the IRV-IPV microneedle patch to support future clinical trials. An IRV-IPV patch has the potential to overcome the limitations of currently licensed oral rotavirus vaccines that sometimes have limited efficacy in developing countries and to contribute to the goal of polio eradication by replacing the oral polio vaccine, which is known to cause vaccine-derived polio.